<DOC>
	<DOCNO>NCT00003297</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient stage III stage IV ovarian cancer recur respond previous chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Stage III Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity topotecan , mitoxantrone , thiotepa give combination follow autologous peripheral blood stem cell transplantation patient recurrent refractory platinum resistant epithelial ovarian cancer . II . Determine progression-free survival overall survival patient therapy . OUTLINE : This dose escalation study topotecan . All patient peripheral stem cell collect . Patients receive topotecan accord escalate dose schedule , mitoxantrone thiotepa fix dose schedule . Patients receive topotecan continuous infusion 24 hour day 1-3 , mitoxantrone intravenously 1 hour day 1-3 , thiotepa intravenously 4 hour day 1-3 , follow 48 hour later infusion peripheral stem cell . Patients may receive second course chemotherapy peripheral stem cell transplantation absence disease progression unacceptable toxicity . Dose escalation topotecan continue cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 patient experience dose limit toxicity . Patients follow every week first month , every month 6 month , every 3 month 1 year , every 6 month . PROJECTED ACCRUAL : A total 21-50 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV epithelial ovarian cancer refractory platinum therapy relapse within 12 month platinum therapy Minimal residual disease laparotomy Must adequate number peripheral stem cell collect No intraabdominal , pelvic disease , disease great 1 cm No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) Serum transaminases less 2 time ULN Renal : Creatinine clearance great 60 mL/min Cardiovascular : Cardiac ejection fraction least 45 % No active angina No uncontrolled hypertension Pulmonary : FEV1 , vital capacity , diffusion capacity great 50 % predict Other : Not HIV positive No active hepatitis B C infection Not pregnant No concurrent malignancy except basal cell squamous cell carcinoma skin No serious medical condition uncontrolled diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy : No immunotherapy within past 4 week No concurrent immunotherapy Chemotherapy : No chemotherapy within past 4 week No mitomycin within past 6 week No concurrent chemotherapy No prior anthracycline therapy great 200 mg/m2 Endocrine therapy : Not specify Radiotherapy : No radiotherapy within past 4 week No concurrent radiotherapy No prior radiotherapy whole abdomen Surgery : Prior surgery allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>